JP2015523407A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523407A5
JP2015523407A5 JP2015524803A JP2015524803A JP2015523407A5 JP 2015523407 A5 JP2015523407 A5 JP 2015523407A5 JP 2015524803 A JP2015524803 A JP 2015524803A JP 2015524803 A JP2015524803 A JP 2015524803A JP 2015523407 A5 JP2015523407 A5 JP 2015523407A5
Authority
JP
Japan
Prior art keywords
dose range
pharmaceutical composition
dimethyl fumarate
composition according
laquinimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523407A (ja
Filing date
Publication date
Priority claimed from EP12179232.9A external-priority patent/EP2692343A1/en
Application filed filed Critical
Publication of JP2015523407A publication Critical patent/JP2015523407A/ja
Publication of JP2015523407A5 publication Critical patent/JP2015523407A5/ja
Pending legal-status Critical Current

Links

JP2015524803A 2012-08-03 2013-08-02 多発性硬化症を処置するための併用療法 Pending JP2015523407A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12179232.9A EP2692343A1 (en) 2012-08-03 2012-08-03 Combination therapy for treatment of multiple sclerosis
EP12179232.9 2012-08-03
US201261712008P 2012-10-10 2012-10-10
EP12187939.9A EP2692344A1 (en) 2012-08-03 2012-10-10 Combination therapy for treatment of Multiple sclerosis
EP12187939.9 2012-10-10
US61/712,008 2012-10-10
PCT/EP2013/066285 WO2014020156A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018107836A Division JP2018150375A (ja) 2012-08-03 2018-06-05 多発性硬化症を処置するための併用療法

Publications (2)

Publication Number Publication Date
JP2015523407A JP2015523407A (ja) 2015-08-13
JP2015523407A5 true JP2015523407A5 (https=) 2016-09-23

Family

ID=47008405

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015524803A Pending JP2015523407A (ja) 2012-08-03 2013-08-02 多発性硬化症を処置するための併用療法
JP2018107836A Pending JP2018150375A (ja) 2012-08-03 2018-06-05 多発性硬化症を処置するための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018107836A Pending JP2018150375A (ja) 2012-08-03 2018-06-05 多発性硬化症を処置するための併用療法

Country Status (20)

Country Link
US (2) US20150164849A1 (https=)
EP (4) EP2692343A1 (https=)
JP (2) JP2015523407A (https=)
KR (3) KR20210147083A (https=)
CN (3) CN104684553A (https=)
AU (3) AU2013298517A1 (https=)
CA (2) CA3107367A1 (https=)
DK (1) DK2879672T3 (https=)
EA (1) EA201590166A8 (https=)
ES (1) ES2674947T3 (https=)
HR (1) HRP20180939T1 (https=)
HU (1) HUE038382T2 (https=)
LT (1) LT2879672T (https=)
PL (1) PL2879672T3 (https=)
PT (1) PT2879672T (https=)
RS (1) RS57567B1 (https=)
SI (1) SI2879672T1 (https=)
SM (1) SMT201800380T1 (https=)
TR (1) TR201808859T4 (https=)
WO (1) WO2014020156A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
CN120053638A (zh) 2016-08-15 2025-05-30 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
ES2957112T3 (es) * 2019-09-11 2024-01-11 Novartis Ag Tratamiento del RMS mediante cambio de terapia
US20230099229A1 (en) 2020-03-13 2023-03-30 Reprise Pharmaceuticals, Inc. Methods of treating multiple sclerosis
WO2021148683A2 (en) * 2020-05-06 2021-07-29 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
CN116672325B (zh) * 2023-06-06 2024-09-03 哈尔滨工业大学 一种包覆中性粒细胞膜的聚芬戈莫德纳米前药的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915334A2 (en) 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
WO2010079222A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
HUE025878T2 (en) 2010-02-12 2016-05-30 Biogen Ma Inc Neuroprotection in demyelinating diseases
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Similar Documents

Publication Publication Date Title
JP2015523407A5 (https=)
JP2015057451A5 (https=)
JP2016147915A5 (https=)
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
JP2012255026A5 (https=)
JP2015038135A5 (https=)
JP2015083580A5 (https=)
JP2012193216A5 (https=)
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
NZ605469A (en) Nalbuphine-based formulations and uses thereof
JP2017506624A5 (https=)
JP2014198723A5 (https=)
JP2015537009A5 (https=)
PH12014501408A1 (en) Immediate release multi unit pellet system
MY206893A (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
JP2014507475A5 (https=)
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
HRP20221344T1 (hr) Novi pripravak acetaminofenskog spoja bez nuspojave po jetru
HRP20220701T1 (hr) Spojeni benzazepini za liječenje touretteova sindroma
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
PH12019502767A1 (en) Oral pharmaceutical formulations of remogliflozin
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου